High blood pressure, affecting approximately 1.3 billion individuals globally, often remains uncontrolled or resistant to treatment, significantly elevating the risk of serious health issues such as heart attacks and strokes. In the UK, around 14 million people are currently managing hypertension.
International Study on Baxdrostat
The BaxHTN trial, spearheaded by Professor Bryan Williams from the UCL Institute of Cardiovascular Science and supported by AstraZeneca, explored the efficacy of a novel oral medication named baxdrostat. This extensive study involved nearly 800 participants across 214 clinics worldwide.
The findings were showcased at the European Society of Cardiology (ESC) Congress 2025 in Madrid and published in the New England Journal of Medicine.
Notable Blood Pressure Reductions
After a 12-week treatment period, patients receiving baxdrostat (1 mg or 2 mg daily) demonstrated an average decrease in blood pressure of approximately 9 to 10 mmHg compared to those on a placebo. Such a reduction is significant enough to lower the likelihood of cardiovascular incidents.
Remarkably, about 40% of participants on baxdrostat achieved healthy blood pressure levels, contrasting with fewer than 20% in the placebo cohort.
Professor Williams remarked, "The nearly 10 mmHg reduction in systolic blood pressure observed with baxdrostat in the BaxHTN Phase III trial is exhilarating, as it correlates with a markedly lower risk of heart attack, stroke, heart failure, and kidney disease."
Mechanism of Action
Blood pressure regulation is closely linked to aldosterone, a hormone responsible for managing salt and water balance in the body. Excessive production of aldosterone can lead to increased salt and water retention, complicating blood pressure control.
Baxdrostat operates by inhibiting aldosterone production, addressing a fundamental contributor to hypertension.
Innovative Treatment for Challenging Cases
According to Professor Williams, "These results represent a significant leap forward in both treatment options and our comprehension of difficult-to-manage hypertension. Many individuals currently treated do not achieve effective control, and this number may be underestimated, particularly as target blood pressure levels have become more stringent."
"The addition of baxdrostat to existing antihypertensive therapy resulted in meaningful systolic blood pressure reductions, lasting up to 32 weeks, without any unforeseen safety concerns. This underscores aldosterone's crucial role in challenging hypertension cases and offers a beacon of hope for enhanced treatment strategies."
Global Impact and Future Prospects
Historically, hypertension was predominantly observed in affluent Western nations, but shifts in dietary habits have increased its prevalence in Eastern and lower-income regions. Currently, over half of those with hypertension reside in Asia, with significant populations in China and India.
Professor Williams noted, "The implications of this drug could extend to nearly half a billion individuals worldwide, including around 10 million in the UK, particularly as we adjust our target blood pressure goals."